Patients treated with pegIFNα 2a had significantly higher risk of thrombocytopenia, and carriers of the SOCS3 rs4969170 AA genotype had significantly lower risk of thrombocytopenia (Table 7). The gene discussed is SOCS3; the disease is Thrombocytopenia.